Current prognostic tools for glioma primarily rely on factors such as WHO grade, IDH mutations, 1p/19q codeletion, MGMT promoter methylation, TERT promoter mutations and EGFR amplification (63). This evidence concerns the gene EGFR and central nervous system cancer.